Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences:
百濟神州（Nasdaq: ZYME）是一家臨床階段的生物技術公司，開發多功能生物治療藥物，旨在改善難治療疾病的治療標準。今天宣佈管理團隊將參加以下即將舉行的投資者會議：
- Piper Sandler 36th Annual Healthcare Conference: Zymeworks' management will participate in one-on-one meetings and present on December 3 at 1:30 pm Eastern Time (ET) in New York, NY.
- Citi's 2024 Global Healthcare Conference: Zymeworks' management will participate in one-on-one meetings and a panel discussion titled: 'Novel Antibody Mechanisms in Oncology' on December 3 at 3:15 pm ET in Miami, FL.
- 7th Annual Evercore HealthCONx Conference: Zymeworks' management will participate in one-on-one meetings and a fireside chat on December 4 at 7:55 am ET in Coral Gables, FL.
- 43rd Annual J.P. Morgan Healthcare Conference: Zymeworks' management will participate in one-on-one meetings on January 13-16, 2025, and a corporate presentation on January 16 at 8:15 am Pacific Time (PT) in San Francisco, CA.
- 第36屆Piper Sandler年度醫療保健大會：百濟神州管理團隊將於12月3日下午1:30（美東時間）在紐約參加一對一會議並發表演講。
- 花旗銀行2024年全球醫療保健大會：zymeworks管理層將於12月3日下午3:15在佛羅里達邁阿密參加一對一會議和標題爲：「腫瘤學中的新型抗體機制」面板討論。
- 第7屆愛文思控股HealthCONx大會：zymeworks管理團隊將於12月4日上午7:55在佛羅里達州科勒爾蓋布爾斯參加一對一會議和爐邊聊天。
- 第43屆摩根士丹利年度醫療保健大會：百濟神州管理團隊將於2025年1月13-16日進行一對一會議，並於1月16日上午8:15（太平洋時間）在加利福尼亞州舊金山舉行企業演示。
In addition, Zymeworks will present an update on its preclinical research programs at their Research & Development Day, taking place virtually and in-person on December 12, 2024, in New York, NY. This event, led by Paul Moore, PhD, Zymeworks' Chief Scientific Officer, will feature:
此外，百濟神州將在2024年12月12日舉行的研究與開發日上更新其臨床前研究項目。這個由百濟神州首席科學官Paul Moore博士主持的活動將以虛擬方式和實地方式在紐約舉行。
- Updates on our portfolio of solid tumor targeting antibody-drug conjugates and T-cell Engager (TCE) molecules, featuring key opinion leaders from these therapeutic areas who will join the Company's management team to discuss ongoing R&D and clinical activities;
- Candidate nomination from our Trispecific TCE platform as the last product candidate in our '5 by 5' R&D strategy; and
- Strategy and rationale for potential expansion into new therapeutic areas in hematological cancers and autoimmune and inflammatory diseases and preclinical development progress on potential investigational new drug applications for new product candidates in 2026 and beyond.
- 關於我們的固體腫瘤靶向抗體藥物結合物和T細胞互結物（TCE）分子組合的最新進展，將有這些治療領域的主要意見領袖加入公司管理團隊，共同討論正在進行的研發和臨床活動；
- 我們三特異性TCE平台的候選人提名作爲我們「5x5」研發策略中的最後一個產品候選者；以及
- 潛在擴展到血液腫瘤和自身免疫性和炎症性疾病等新治療領域的策略和理由，以及2026年及以後新產品候選者的潛在探索性新藥申請的臨床前開發進展。
To register your participation for Zymeworks' Research & Development Day, please click here.
要註冊參加Zymeworks研發日，請點擊這裏。
About Zymeworks Inc.
關於Zymeworks股份有限公司。Zymeworks是一家全球性的臨床階段生物技術公司，致力於發現、開發和商業化新型多功能生物治療藥物。Zymeworks的使命是爲那些受到難以治療的癌症和其他疾病影響的人們帶來有意義的變化。公司的互補治療平台和完全集成的藥物開發引擎爲精密工程和開發高度差異化的基於抗體的治療候選藥物提供了靈活性和兼容性。Zymeworks通過公司專有的Azymetric技術開發了zanidatamab，一種HER2靶向的雙特異性抗體。Zymeworks與百濟神州有限公司（BeiGene）和爵士製藥愛爾蘭有限公司（Jazz）簽訂了不同的協議，授予其在不同領域開發和商業化zanidatamab的獨家權利。目前，Zanidatamab正在多個全球臨床試驗中評估，作爲潛在的治療HER2過度表達癌症的最佳選擇。一份針對先前治療的不可切除的局部晚期或轉移性HER2陽性膽管癌（BTC）的治療的生物合成執照申請(BLA)已被美國食品和藥物管理局（FDA）接受並獲得優先審查。中國國家藥品監督管理局（NMPA）藥物審評中心（CDE）也接受了BLA的審查。如果獲得批准，zanidatamab將成爲針對BTC在美國和中國獲得批准的第一個HER2靶向治療。Zymeworks正在通過使用其在抗體-藥物結合和多特異性抗體治療方面的體驗和能力，在多個新穎靶標中的表示區域具有顯著未滿足的醫學需求框架中，快速推進具有深度管道的產品候選藥物，除了Zymeworks的完全擁有的管道外，其治療平台已通過與全球生物製藥公司的戰略合作得到進一步利用。有關Zymeworks的信息，請訪問以下網站，並在X上關注@ZymeworksInc。
Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks' mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company's complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company's proprietary Azymetric technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. The U.S. FDA granted accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC). Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive BTC in the U.S. A BLA has also been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are now actively recruiting with investigational new drug applications for ZW220 and ZW251 planned for 2025. In addition to Zymeworks' pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit and follow @ZymeworksInc on X.
Zymeworks是一家全球性臨床階段的生物技術公司，致力於發現、開發和商業化新穎、多功能生物治療藥物。Zymeworks的使命是對那些受到難治性癌症和其他疾病影響的人們產生有意義的影響。公司的互補治療平台和完全集成的藥物開發引擎提供了精確工程和開發高度差異化的基於抗體的治療候選藥物的靈活性和兼容性。Zymeworks利用公司專有的Azymetric技術，設計和開發了針對HER2的雙特異性抗體zanidatamab。Zymeworks已與百濟神州公司（BeiGene）和爵士製藥愛爾蘭有限公司（Jazz）簽訂了單獨協議，分別授予兩家公司在不同領域開發和商業化zanidatamab的獨家權利。Zanidatamab目前正在全球多個臨床試驗中評估，作爲治療HER2表達癌症患者的潛在首選治療方案。美國FDA已加速批准Ziihera（zanidatamab-hrii）50mg/mL用於注射靜脈用於治療先前治療過的、不可切除或轉移性HER2陽性（IHC 3+）膽道癌（BTC）的成人。Ziihera是美國首款也是唯一獲得批准用於治療HER2陽性BTC的雙重HER2靶向抗體。中國藥監局（CDE）已接受BLA申請，由中國國家藥品監督管理局（NMPA）審核。Zymeworks正在迅速推進一個龐大的自主產品候選藥物管線，利用其在抗體藥物結合物和多特異抗體治療領域的專業知識，針對有重大未滿足醫療需求的領域中的新途徑。ZW171和ZW191的I期研究現在正在積極招募，計劃2025年提交ZW220和ZW251的探索性新藥申請。除了Zymeworks的藥物管線外，通過與全球生物製藥公司的戰略伙伴關係，其治療平台已進一步利用。有關Zymeworks的信息，請訪問 並關注@SpringWorksTxzymeworks 公司在X上。
Contacts:
聯繫人：
Investor Inquiries:
投資者諮詢：
Shrinal Inamdar
Director, Investor Relations
(604) 678-1388
ir@zymeworks.com
Shrinal Inamdar
投資者關係董事
(604) 678-1388
ir@zymeworks.com
Media Inquiries:
媒體查詢：
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com
Diana Papove
高級董事，企業通信
(604) 678-1388
media@zymeworks.com
譯文內容由第三人軟體翻譯。
